Cargando…
Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia
SUMMARY: Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404468/ https://www.ncbi.nlm.nih.gov/pubmed/28458896 http://dx.doi.org/10.1530/EDM-16-0126 |
_version_ | 1783231603601833984 |
---|---|
author | Geilswijk, Marianne Andersen, Lise Lotte Frost, Morten Brusgaard, Klaus Beck-Nielsen, Henning Frederiksen, Anja Lisbeth Jensen, Dorte Møller |
author_facet | Geilswijk, Marianne Andersen, Lise Lotte Frost, Morten Brusgaard, Klaus Beck-Nielsen, Henning Frederiksen, Anja Lisbeth Jensen, Dorte Møller |
author_sort | Geilswijk, Marianne |
collection | PubMed |
description | SUMMARY: Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, also during pregnancy. LEARNING POINTS: Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia. Hypoglycemia during pregnancy may have serious health implications for mother and fetus. Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment may pose a risk of fetal growth restriction. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only. |
format | Online Article Text |
id | pubmed-5404468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-54044682017-04-28 Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia Geilswijk, Marianne Andersen, Lise Lotte Frost, Morten Brusgaard, Klaus Beck-Nielsen, Henning Frederiksen, Anja Lisbeth Jensen, Dorte Møller Endocrinol Diabetes Metab Case Rep Error in Diagnosis/Pitfalls and Caveats SUMMARY: Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, also during pregnancy. LEARNING POINTS: Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia. Hypoglycemia during pregnancy may have serious health implications for mother and fetus. Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment may pose a risk of fetal growth restriction. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only. Bioscientifica Ltd 2017-02-15 /pmc/articles/PMC5404468/ /pubmed/28458896 http://dx.doi.org/10.1530/EDM-16-0126 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) . |
spellingShingle | Error in Diagnosis/Pitfalls and Caveats Geilswijk, Marianne Andersen, Lise Lotte Frost, Morten Brusgaard, Klaus Beck-Nielsen, Henning Frederiksen, Anja Lisbeth Jensen, Dorte Møller Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia |
title | Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia |
title_full | Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia |
title_fullStr | Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia |
title_full_unstemmed | Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia |
title_short | Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia |
title_sort | octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia |
topic | Error in Diagnosis/Pitfalls and Caveats |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404468/ https://www.ncbi.nlm.nih.gov/pubmed/28458896 http://dx.doi.org/10.1530/EDM-16-0126 |
work_keys_str_mv | AT geilswijkmarianne octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia AT andersenliselotte octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia AT frostmorten octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia AT brusgaardklaus octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia AT becknielsenhenning octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia AT frederiksenanjalisbeth octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia AT jensendortemøller octreotidetherapyandrestrictedfetalgrowthpregnancyinfamilialhyperinsulinemichypoglycemia |